Patent: 5,447,725

Summary for Patent: 5,447,725

Title:	Methods for aiding periodontal tissue regeneration
Abstract:	Methods for aiding periodontal tissue regeneration with compositions containing bioresorbable polymers, leachable solvents, and bioavailable drug actives. The compositions useful for these methods are characterized by becoming harder upon contact with the periodontal tissue such that the composition is effective for aiding tissue regeneration and by releasing a therapeutically-effective amount of drug active agent.
Inventor(s):	Damani; Nalinkant C. (Cincinnati, OH), Mohl; Douglas C. (Fairfield, OH), Singer, Jr.; Robert E. (Fairfield, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	08/076,304
Patent Claims:	see list of patent claims

Comprehensive Patent Landscape Analysis of United States Patent 5,447,725 (Periodontal Tissue Regeneration Using Bioresorbable Polymer/Leachable Solvent and Drug-Releasing “Hardening” Composition)

US Patent 5,447,725 claims a drug delivery method for periodontal tissue regeneration using a composition that (i) includes a bioresorbable polymer, (ii) a leachable solvent, and (iii) a bioavailable drug active agent, where the composition “becomes harder upon contact with the periodontal tissue” and releases a therapeutically effective amount of the drug active. The claims are drafted broadly to cover many polymers, solvents, drug classes, and specific drugs, but they also rely on functional characterization (hardening and controlled release) that can narrow practical enforceability depending on claim construction and the specific technology used by competitors.

This analysis maps (1) what the claims actually cover, (2) the likely claim construction pressure points, (3) the patent estate context around periodontal local drug delivery using bioresorbable polymers and in situ hardening matrices, (4) how the claims can be challenged (invalidity and non-infringement), (5) where litigation risk tends to concentrate (materials/solvent/drug selection and in situ hardening mechanism), and (6) the key competitive design-arounds.

---

What does US Patent 5,447,725 claim for periodontal tissue regeneration?

Executive answer: The patent claims a method (not a device) in which a clinician places or syringes at a periodontal site a drug-loaded, bioresorbable polymer composition that contains a leachable solvent and hardens in contact with periodontal tissue, and thereby provides drug release to aid regeneration.

Independent claim structure (Claim 1)

Claim 1 requires, in one method:

1. Placement at a periodontal tissue regeneration site (human or lower animal).
2. Composition comprises:
   • Bioresorbable polymer
   • Leachable solvent
   • Bioavailable drug active agent
3. Composition is characterized by:
   • “Becoming harder upon contact with periodontal tissue”
   • Releasing a therapeutically effective amount of the drug active agent

The “hardening” and “release” limitations are functional. In practice, they often require showing an in situ phase change or viscosity/rigidity increase and an associated elution profile in the claimed composition system.

Dependent claim expansion

Claims 2-6 and 7-9 and 11-13 systematically narrow or specify:

• Polymer selection: PLA, PGA, PLGA (and a longer list in claim 2).
• Solvent selection: propylene carbonate, glyceryl triacetate, triethyl citrate.
• Drug-active classes: antibacterial/antibiotics/anti-inflammatories/stimulatory/dentinal desensitizing/immune/local anesthetic/nutritional/antioxidants/LPS complexing/peroxides/growth factors/clot stabilizing factors.
• Specific drug list: includes multiple antibiotics, NSAIDs, antiseptics, fluoride, lidocaine/benzocaine, insulin, PDGF/BMP-related factors, IGF-1, fibrin/factor IX complex, etc.
• Dosage form placement: claim 10 and 14 add syringeable fluid/viscous gel adjacent to tooth surface.
• Quantification: claim 11 adds percentage ranges for polymer/solvent/drug active.
• PLGA composition: claim 12 specifies lactide/glycolide molar fractions and molecular weight.

What is the core novelty theme (as drafted)?

The claim set ties together three elements that commonly appear in periodontal local delivery:

• A bioresorbable matrix to retain drug and degrade.
• A leachable solvent/plasticizer or pore-former to support mass transport or create a release pathway.
• A controlled in situ mechanical transition (“becomes harder”) when placed into the periodontal environment.

That combination reads like a local depot intended to be injectable, then solidify/harden, then elute.

---

How strong are the functional “hardens upon contact” and “releases therapeutically effective amount” limitations?

Executive answer: These are the highest-friction limitations for both validity and infringement because they are functional and mechanism-sensitive. For enforcement, the patent typically needs to pin down what “hardening” means (time/degree/conditions) and what release profile is “therapeutically effective” in periodontal tissue.

Claim construction pressure points

1. Hardens upon contact

   • Key question for claim interpretation is whether “harder” is merely higher viscosity/gelation or must be a solidification that prevents washout.
   • In litigation, this becomes a claim scope lever: accused products can argue they do not harden in the claimed manner (or that any viscosity change is not “upon contact with periodontal tissue” in the required sense).

2. Releasing a therapeutically effective amount

   • “Therapeutically effective” is broad but not empty. Courts typically require that the accused composition, when placed as claimed, can deliver drug to achieve the intended therapeutic effect.
   • For non-infringement, defendants can argue insufficient release or release occurs before placement or through a route not meeting the claimed method.

3. System-wide “wherein said composition is further characterized by…”

   • The claim ties both properties to “said composition,” supporting arguments that both hardening and release are necessary features of the same formulation system.

---

Which polymers, solvents, and drugs are explicitly covered by US 5,447,725?

Executive answer: The patent specifies a finite universe of polymers and solvents, then expands drug coverage to large classes and enumerates many individual actives.

Polymers

• Claim 2 list (broader):

  • Polylactic acid (PLA)
  • Polyglycolic acid (PGA)
  • Poly lactyl-co-glycolic acid (PLGA)
  • Polyaminoacids
  • Chitosan
  • Collagen
  • Polyalbumin
  • Gelatin
  • Hydrolyzed animal protein
  • Water soluble gums
  • Polyanhydride
  • Poly orthoesters

• Claims 6 and 7 narrow:

  • PLA, PGA, PLGA

• Claim 11 and 12 focus on PLGA with quantified monomer ratios and molecular weight.

Leachable solvents

• Claim 3 and 7/11 list:
  • Propylene carbonate
  • Glyceryl triacetate
  • Triethyl citrate
  • Mixtures

This is a meaningful constraint. Many periodontal injectables use different excipients (saline vehicles, carboxy methylcellulose gels, hyaluronic acid, PEG systems, crosslinked hydrogels). Moving off this solvent set is an obvious design-around.

Drug actives

• Claim 4 covers:
  • Antibacterial/antibiotics
  • Anti-inflammatory
  • Stimulatory agents
  • Dentinal desensitizing agents
  • Odor masking
  • Immune reagents
  • Local anesthetics
  • Nutritional agents
  • Antioxidants
  • LPS complexing agents
  • Peroxides
  • Growth factors
  • Clot stabilizing factors
• Claim 5 and 9 enumerate many individual agents including:
  • Antibiotics: tetracycline, neomycin, kanamycin, metronidazole, clindamycin
  • Antiseptics/iodine: iodine
  • NSAIDs/analgesics: aspirin, naproxen, ibuprofen, flurbiprofen, indomethacin
  • Steroid: hydrocortisone
  • Local anesthetics: lidocaine, benzocaine
  • Fluoride: sodium fluoride
  • Proteins/growth factors: PDGF, BMPs, TGF-β, IGF-1, fibrin, factor IX complex

Enforcement risk shifts depending on whether competitors use any listed drug (direct inclusion) versus analogs or different actives (potential non-infringement).

---

Does US 5,447,725 cover a “syringeable” periodontal gel depot?

Executive answer: Yes. Claims 10 and 14 add the limitation that placement is by syringing and that the composition is a fluid or viscous gel capable of being syringed adjacent to tooth surface.

What this likely captures

• Injectable delivery systems that can be expressed into periodontal pockets.
• Formulations that maintain shape/retention long enough for degradation and release.

What it likely excludes

• Prefabricated membranes or fibers unless they can be framed as being placed by syringing into situ in the claimed form.
• Solid inserts not syringeable as “fluid or viscous gel.”

---

How do percentage and PLGA molecular parameters narrow claim scope?

Executive answer: Claims 11-13 provide quantitative narrowing that can materially affect infringement analysis and invalidity assessments.

Claim 11 ranges

• Polymer: about 1% to 90% (PLGA specifically in claim 11)
• Leachable solvent: about 0.1% to 90%
• Drug active: about 0.1% to 90%

These wide ranges can still read on many formulations, but they give defendants additional pathways to argue out-of-range amounts.

Claim 12 PLGA composition and MW

• Lactide: about 15% to 85% molar
• Glycolide: about 15% to 85% molar
• Number average molecular weight: about 1,000 to 120,000

This narrows to PLGA chemistries within a common manufacturing envelope, but the MW range can be a key differentiator if competitors use ultra-low MW PLGA or higher MW grades outside these bounds.

---

What competing periodontal regeneration products would be most at risk under this claim set?

Executive answer: The most at-risk products are those using:

• PLGA or other bioresorbable polymers,
• a listed leachable solvent (propyl carbonate or the listed glyceride/ester plasticizers),
• a drug depot with in situ hardening/gelation,
• syringe delivery into periodontal sites,
• and one of the enumerated drugs or drug classes.

Commercial risk hotspots by claim element

1. Solvent substitution risk
   • If a competitor uses propylene carbonate, glyceryl triacetate, or triethyl citrate as the leachable solvent/plasticizer, they are structurally closer.
2. Hardening mechanism
   • In situ hardening driven by solvent leaching plus polymer glass transition change, precipitation, or gelation is the likely match. If hardening instead comes from different chemistries (e.g., light curing, ionic crosslinking with calcium, enzymatic crosslinking), the “hardens upon contact” limitation can become a differentiator.
3. Drug enumerations
   • If the active is one of the listed drugs (tetracycline, metronidazole, clindamycin, NSAIDs, lidocaine, hydrocortisone, fluoride, PDGF/BMP/TGF-β/IGF-1 family, etc.), the pharmaceutical-level infringement argument strengthens.

---

What patents and prior art themes likely overlap with US 5,447,725?

Executive answer: The patent belongs to a well-developed technology area: local periodontal therapy using bioresorbable polymer depots. The most relevant prior art themes typically include in situ forming depots, injectable drug-loaded polymer systems, and periodontal-specific delivery using PLGA and other biodegradable polymers.

Overlapping prior art categories

1. In situ forming biodegradable depots
   • Polymer dissolved in a solvent/plasticizer that is removed/leached after placement, changing mechanical properties and drug release.
2. Periodontal local drug delivery matrices
   • Systems intended to deliver antibiotics, antiseptics, anti-inflammatories, or growth factors locally rather than systemically.
3. PLGA-based controlled release in dentistry
   • Drug elution kinetics based on polymer composition and molecular weight.
4. Injectable viscous gels for pocket application
   • Delivery systems that can be expressed near tooth surfaces.

How overlap affects novelty/validity

Given the breadth of polymer and drug lists, validity typically turns on whether the specific combination:

• uses the claimed solvent set,
• achieves the claimed “hardening upon contact” behavior,
• and targets periodontal tissue regeneration, was already disclosed in a single enabling reference or in an obvious combination.

---

What are the most likely invalidity routes against US 5,447,725?

Executive answer: The highest-probability invalidity theories are anticipation or obviousness based on prior art showing (a) injectable bioresorbable polymer + leachable solvent depots with (b) in situ hardening and (c) drug release for periodontal indications.

Anticipation (35 USC 102)

• A reference that discloses every limitation of Claim 1 including:
  • the specific polymer/solvent/drug system (or functionally equivalent compositions that still meet the claim’s categorical lists),
  • placement for periodontal regeneration,
  • hardening upon contact with periodontal tissue,
  • therapeutic release.

Given the enumerations, anticipation depends on whether a reference explicitly uses one of the enumerated polymers and solvents and supports “periodontal tissue regeneration” with the claimed drug behavior.

Obviousness (35 USC 103)

Even if exact hardening or solvent list is not identical, obviousness can still succeed if prior art teaches:

• injectable bioresorbable depots for local periodontal therapy,
• a recognized technique to obtain in situ hardening by solvent leaching,
• and using known drug actives in known periodontal contexts.

Here, the solvent selection can be the battleground. If the solvent selection is presented as a routine leachable solvent class, it can be attacked as obvious.

Indefiniteness / enablement

Functional language like “becoming harder” can be challenged if the patent does not specify how much hardening and under what conditions. However, indefiniteness/enablement outcomes depend on the specification’s detail and prosecution history, which are not provided in the prompt.

---

How would a competitor design around US 5,447,725?

Executive answer: Design-arounds are most direct at the solvent, hardening mechanism, and drug actives levels.

Design-around levers

1. Change the leachable solvent system
   • Use a solvent/plasticizer not listed (e.g., PEG-based systems, ethanol-water mixtures, different ester excipients), or avoid solvent leaching as the hardening driver.
2. Use a different hardening trigger
   • If hardening comes from crosslinking chemistry, thermal curing, or ionic gelation not linked to solvent leaching upon contact, defendants argue they don’t meet the “becomes harder upon contact” limitation.
3. Use different polymer system or molecular parameters
   • Claim 6-7 constrain polymer sets (PLA/PGA/PLGA). Claim 2 allows many other polymers, but other systems can still be avoided by selecting polymers that do not align with the categorical list or by moving out of Claim 11-12 ranges where those narrower claims are asserted.
4. Use non-enumerated actives
   • Swap to actives outside Claim 5/9 enumerations. If actives remain within the enumerated list, substitution is not available.
5. Avoid syringeable fluid/viscous gel form
   • Use membranes, strips, fibers, or injectable suspensions that do not meet the “fluid or viscous gel capable of being syringed adjacent to tooth surface” limitation as construed.

---

How does the patent likely interact with FDA approval categories and Orange Book listings?

Executive answer: As written, US 5,447,725 is a method claim using described compositions. Enforcement against a marketed product typically requires:

• a product that is used “by placing” the composition in periodontal tissue,
• a match to the claim’s composition limitations,
• and a demonstrated hardening and release profile consistent with the claimed method.

Orange Book listings apply to approved drug products with patents covering drugs used under the FDA approval; whether this patent is listed depends on the specific NDA/ANDA/BLA product assignments and listing decisions. Those details are not contained in the prompt, so no listing status is provided here.

---

Key infringement scenarios: where does exposure concentrate?

Executive answer: Exposure concentrates in combinations that satisfy all of:

• polymer + leachable solvent from the specified sets,
• in situ hardening upon periodontal contact,
• drug active within the enumerated list or at least within the specified class (depending on which claims are asserted),
• and placement by syringeable delivery.

Scenario A: injectable PLGA depot with propylene carbonate and tetracycline

• High risk if the formulation is placed as an injectable and the solvent-leaching produces hardening in the pocket, with tetracycline release over time.

Scenario B: PLGA depot with a different solvent

• Lower risk if the leachable solvent is outside the enumerated list and cannot be mapped to the “leachable solvent selected from…” requirement.

Scenario C: different hardening mechanism

• Medium-to-low risk if hardening occurs via a distinct crosslinking pathway unrelated to “upon contact with periodontal tissue” as characterized.

---

When does exclusivity expire?

Executive answer: Patent term for a US utility patent is generally constrained by filing date and any patent term adjustments/extensions, but those specifics are not provided in the prompt. Without the application filing date, term adjustment data, and expiration/maintenance record, a precise exclusivity timeline cannot be stated.

---

Key Takeaways

• US 5,447,725 claims a method for periodontal tissue regeneration using an injectable, bioresorbable polymer + specified leachable solvent + drug active composition that hardens upon periodontal contact and releases therapeutic drug.
• The enforcement-critical limitations are the functional requirements that the composition hardens upon contact and releases a therapeutically effective amount.
• Claim scope is constrained by explicit solvent selections (propylene carbonate, glyceryl triacetate, triethyl citrate) and, in narrower claims, by PLGA composition and molecular weight.
• Design-arounds are most practical by changing the solvent system, changing the hardening mechanism, using actives outside the enumerated drug list, or avoiding the syringeable viscous gel placement paradigm.
• Validity and infringement risk both hinge on whether prior art or accused products disclose the same in situ hardening behavior tied to the solvent-leaching concept and the claimed periodontal regeneration use.

---

FAQs

1. What is the main claim limitation in US 5,447,725 that can be hardest to prove in litigation?

The functional “composition becomes harder upon contact with periodontal tissue” and “releases a therapeutically-effective amount” limitations, which require evidence of in situ mechanical change and clinically meaningful drug release in the periodontal environment.

2. Does US 5,447,725 claim a specific periodontal pocket size, tissue target, or procedure?

No. The claims broadly require placement at a site in need of periodontal tissue regeneration and include a syringeable placement variant, but they do not specify pocket geometry or a particular surgical instrument beyond syringe delivery in dependent claims.

3. Are all drug actives covered equally by the independent claim?

No. The independent Claim 1 covers “bioavailable drug active agents” generally, but dependent claims enumerate drug classes and list specific agents, creating tiers of scope depending on which claims are asserted.

4. If a competitor uses PLGA but not propylene carbonate or triethyl citrate, are they automatically safe?

Not automatically. The categorical “leachable solvent selected from” limitations can be avoided if the accused formulation uses a non-listed solvent, but competitors still can face risk if other asserted claims do not strictly require those exact solvents or if claim construction treats substituted components as meeting the claimed leachable solvent limitation.

5. Does US 5,447,725 cover non-injectable periodontal depots?

Only if the accused product method can still be argued to meet the method claims. The explicit syringeable viscous gel limitation appears in dependent claims (10 and 14), so non-injectable systems are less likely to infringe those narrower dependent claims.

---

References (APA)

No sources were provided or citable within the prompt beyond the claim text itself.

Details for Patent 5,447,725

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Biologicals Llc	PROFILNINE, PROFILNINE HP, PROFILNINE HT, PROFILNINE SD	factor ix complex	For Injection	102476	July 20, 1981		2013-06-11